Abstract：ObjectiveTo observe the effects of proton pump inhibitor(PPI)combined with gastric motility drugs in the treatment of stable chronic obstructive pulmonary disease (COPD)and gastroesophageal reflux disease(GERD).Methods 90 outpatients with stable COPD and GERD in our hospital from March 2015 to March 2016 were selected and divided into the control group and the intervention group respectively according to the order of treatment.The original treatment about COPD was not changed for both groups and the intervention group was treated with Omeprazole(20 mg,po bid)and Mosapride(5 mg,po tid)for 8 weeks additionally.The reflux diagnostic questionnaire(RDQ)score,St George′s respiratory questionnaire (SGRQ)score,lung function (FEV1%pred)and 6 minute walk distance (6MWD)were compared between the two groups before and after treatment.ResultsCompared with the control group,the RDQ score,each part and the total score of SGRQ in intervention group after treatment was significant lower(P＜0.05),while FEV1%pred and 6MWD had no significant change(P＞0.05).The RDQ score was negatively correlated with FEV1%pred and 6MWD before and after treatment in the two groups,while positively correlated with the score of SGRQ (P＜0.05).ConclusionTreatment with PPI combined with gastric motility drugs can improve clinical symptoms and life quality of patients with COPD coexisting with GERD.
何兵;魏海龙. 抑酸剂联合促胃动力药治疗稳定期COPD合并胃食管反流的效果[J]. 中国当代医药, 2017, 24(23): 37-39.
HE Bingl;WEI Hai-long. Effect of proton pump inhibitor combined with gastric motility drugs in the treatment of stable COPD complicated with gastroesophageal reflux. 中国当代医药, 2017, 24(23): 37-39.
Vogelmeier C，Criner GJ，Martinez FJ，et al.Global strategy for the diagnosis，management and prevention of COPD，global initiative for chronic obstructive lung disease （GOLD）2017[J].Respiralogy，2017，22（3）：575-601.
[2]
Mokhlesi B，Morris AL，Huang CF，et al.Increased prevalence of gastroesophageal reflux symptoms in patients with COPD[J].Chest，2001，119（4）：1043-1048.
[3]
Martinez CH，Okajima Y，Murray S，et al.Impact of self-reported gastroesophageal reflux disease in subjects from COPD gene cohort[J].Respir Res，2014，15（1）：62-71.
[4]
Popadynets′IR.Comparison of the effectiveness Omeprazole and Pantoprazole in the treatment of gastroesophageal reflux disease in patients with asthma[J].Lik Sprava，2013，73（6）：47-53.
[5]
Kahrilas PJ，Howden CVV，Hughes N，et al.Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease[J].Chest，2013，143（3）：605-612.
David TW，Yu MS，Rhonda J，et al.Reliability and validity of a Hong Kong Chinese version of the St George′s respiratory questionnaire in patients with COPD[J].Hong Kong Physiother，2004，22（1）：33-38.
[9]
Naik RD，Vaezi MF.Extra-esophageal gastroesophageal reflux disease and asthma：understanding this interplay[J].Expert Rev Gastroenterol Hepatol，2015，9（7）：969-982.
[10]
Magda S.Susceptibility to exacerbation in chronic obstructive pulmonary disease-data from the ECLIPSE study[J].Maedia，2010，5（3）：223-224.
Han MK，Kazerooni EA，Lynch DA，et al.Chronic obstructive pulmonary disease exacerbations in the COPD gene study：associated radiologic phenotypes[J].Radiology，2011，261（1）：274-282.
[13]
Giuliano C，Wilhelm SM，Kale-Pradhan PB.Are proton pump inhibitors associated with the development of community-acquired pneumonia a meta-analysis[J].Expert Rev Clin Pharmacol，2012，5（3）：337-344.
京公网安备 11010502046607号